Exelixis (NASDAQ: EXEL) Faces Scrutiny After Lowered Revenue Forecast and Analyst Rating

• Exelixis (NASDAQ: EXEL), a biotechnology firm, reported second-quarter revenue of $628.7 million, leading to a lowered full-year 2026 revenue forecast and a subsequent stock drop.
• BMO Capital initiated coverage with a "Market Perform" rating and a $54.00 price target, suggesting limited upside for the cancer treatment stock.
• Legal investigations by Levi & Korsinsky and SueWallSt are underway following the guidance revision and investor losses.

Exelixis (NASDAQ: EXEL) is a biotechnology company with a market capitalization of approximately $13.35 billion. The company focuses on developing new medicines, particularly for cancer treatment. Its stock currently trades at $53.12 per share, having moved between a 52-week low of $33.76 and a high of $57.57.

On August 18, 2026, an analyst from BMO Capital initiated coverage on Exelixis with a "Market Perform" rating, as highlighted by TheFly. This rating suggests the analyst expects the biotech stock to perform in line with the general market. A price target of $54.00 was set, representing a small potential upside of 1.66% from its price at the time.

This neutral outlook follows the company's recent financial report. Exelixis announced second-quarter revenue of approximately $628.7 million, which did not meet analyst expectations. Following this, the company lowered and narrowed its revenue forecast for the full year of 2026, causing its shares to drop in after-hours trading.

The revised guidance was linked to slower-than-expected growth in its neuroendocrine-tumor business. This adjustment came after company executives, including CFO Christopher Senner, had reiterated the original full-year guidance on May 5, 2026, expressing optimism about the company's performance and product growth, as noted by PR Newswire.

Due to the stock's decline after the guidance change, law firms Levi & Korsinsky and SueWallSt have started investigations into potential securities claims. As reported by Business Wire, these firms are looking into the circumstances surrounding the company's revised financial outlook and the subsequent losses suffered by investors.